Tamoxifen retains cancer-preventive efficacy with concomitant hormonal contraceptive in a rat mammary tumorigenesis model
Year: 2026
Type: preprint
Abstract: Whether hormonal contraceptives (HCs) impair tamoxifen efficacy in premenopausal women is unknown. Using a rat estrogen receptor-positive mammary tumorigenesis model, we found that combined HC (17α-ethinylestradiol + levonorgestrel) did not reduce the cancer-preventive tamoxifen efficacy. No cancers occurred with tamoxifen + HC treatment, 16.7% in tamoxifen-alone and 91.7% in controls (p < 0.001). Tamoxifen-associated reproductive adverse events were not increased by HC co-administration. HC use by premenopausal women taking tamoxifen merits clinical evaluation.
Source: Research Square
Institutions: Northwestern University, University of Illinois Chicago
Language: English
Subfield: Endocrinology
Domain: Life Sciences
Open Access status: green
OpenAlex ID: W7235019848
